TIM-3: An emerging target in the liver diseases.

Scand J Immunol

Department of Immunology, Medical College of Qingdao University, Qingdao, China.

Published: April 2020

T cell immunoglobulin domain and mucin domain-containing molecule 3 (TIM-3) is found expression in the surface of terminally differentiated T cells and belongs to the TIM family of type Ⅰ transmembrane proteins. It binds to the ligand Galectin-9 and mediates T cell apoptosis. As the research progresses, TIM-3 is also expressed in Th17, NK, monocyte, which binds to ligand and induce immune peripheral tolerance in both mice and man. Numerous researches have demonstrated that TIM-3 influences liver diseases, including liver-associated chronic viral infection, liver fibrosis, liver cancer et al and suggest new approaches to intervention. Currently, targeted therapy of TIM-3 is a new treatment in the field of immunization. Although many studies have proven that TIM-3 has an inhibitory effect in vivo, the specific mechanism is not clear. Herein, we summarize the important role of TIM-3 in the regulation of liver disease and prospects for future clinical research. TIM-3 will provide new targets for improving clinical liver disease.

Download full-text PDF

Source
http://dx.doi.org/10.1111/sji.12825DOI Listing

Publication Analysis

Top Keywords

tim-3
8
liver diseases
8
binds ligand
8
liver disease
8
liver
6
tim-3 emerging
4
emerging target
4
target liver
4
diseases cell
4
cell immunoglobulin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!